ArticleJournal of global oncology2018
Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report.
Open access · goldAbstract readCase Reports
In one paragraph
Article in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Atezolizumab for Advanced Alveolar Soft Part Sarcoma.The New England journal of medicine · 2023Trial
- Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332.Pediatric blood & cancer · 2026Article
- A partial response to atezolizumab in alveolar soft part sarcoma with near-complete resolution of extensive pulmonary metastases: a case report.Frontiers in oncology · 2026Article
- Complete Response to Nivolumab and Ipilimumab After Pazopanib Discontinuation in a Seven-Year-Old Girl With Alveolar Soft Part Sarcoma: A Case Report and Literature Review.Cancer reports (Hoboken, N.J.) · 2025Review
- Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment.Journal of immunotherapy and precision oncology · 2025Review
- Advances in treatment of alveolar soft part sarcoma: an updated review.Japanese journal of clinical oncology · 2023Review
- Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?Biomarker research · 2023Review
- Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Soft Tissue Leiomyosarcoma With Microsatellite Instability, High Tumor Mutational Burden, and Programmed Death Ligand-1 Expression Showing Pathologic Complete Response to Pembrolizumab: A Case Report.JCO precision oncology · 2022Article
- Review
- Clinical characteristics and outcomes of primary intracranial alveolar soft-part sarcoma: A case report.World journal of clinical cases · 2022Article
- Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy.Frontiers in immunology · 2022Article
- Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.Frontiers in pharmacology · 2022Article
- Alveolar Soft Part Sarcoma of the Oro-Maxillofacial Region in the Pediatric Age Group: Immunohistochemical and Ultrastructural Diagnosis of Two Cases.Head and neck pathology · 2021Article
- Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma.Cancers · 2021Article
- Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.Investigational new drugs · 2021Article
- PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma.Cancer reports (Hoboken, N.J.) · 2021Article
- Immunotherapy for sarcomas: new frontiers and unveiled opportunities.Journal for immunotherapy of cancer · 2021Review
- Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?Cancers · 2021Review
- Deciphering Human Leukocyte Antigen Susceptibility Maps From Immunopeptidomics Characterization in Oncology and Infections.Frontiers in cellular and infection microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Anthony P ConleyAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Van Anh TrinhAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Chrystia M ZobniwAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Kristi PoseyAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Jaime D MartinezAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Oscar G ArrietaAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Wei-Lien WangAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Alexander J LazarAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Neeta SomaiahAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Jason RoszikAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Shreyaskumar R PatelAnthony P. Conley, Van Anh Trinh, Chrystia M. Zobniw, Kristi Posey, Wei-Lien Wang, Alexander J. Lazar, Neeta Somaiah, Jason Roszik, and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Jaime D. Martinez, Universidad Nacional Autonoma de Mexico; and Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Instituto Nacional de Cancerología · MXThe University of Texas MD Anderson Cancer Center · USUniversidad Nacional Autónoma de México · MX
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultHumansMaleProtein Kinase InhibitorsSarcoma, Alveolar Soft PartProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.